1-20 of 33
John C. Byrd
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

B-cell Receptor Pathway Mutations Are Infrequent in Patients with Chronic Lymphocytic Leukemia on Continuous Ibrutinib Therapy

Jennifer A. Woyach, Paolo Ghia, John C. Byrd, Inhye E. Ahn, Carol Moreno, Susan M. O'Brien, Daniel Jones, Leo W.K. Cheung, Elizabeth Chong, Kevin Kwei, James P. Dean, Danelle F. James, Adrian Wiestner
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (16): 3065–3073.
https://doi.org/10.1158/1078-0432.CCR-22-3887
Published: 15 August 2023
View article titled, B-cell Receptor Pathway Mutations Are Infrequent in Patients with Chronic Lymphocytic Leukemia on Continuous Ibrutinib Therapy
Open the PDF for B-cell Receptor Pathway Mutations Are Infrequent in Patients with Chronic Lymphocytic Leukemia on Continuous Ibrutinib Therapy in another window
Includes: Supplementary data
Journal Articles

Selinexor Combined with Ibrutinib Demonstrates Tolerability and Safety in Advanced B-Cell Malignancies: A Phase I Study

Deborah M. Stephens, Ying Huang, Amy S. Ruppert, Janek S. Walker, Daniel Canfield, Casey B. Cempre, Qiang Fu, Sharyn Baker, Boyu Hu, Harsh Shah, Renee Vadeboncoeur, Kerry A. Rogers, Seema Bhat, Samantha M. Jaglowski, Hank Lockman, Rosa Lapalombella, John C. Byrd, Jennifer A. Woyach
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (15): 3242–3247.
https://doi.org/10.1158/1078-0432.CCR-21-3867
Published: 02 August 2022
View article titled, Selinexor Combined with Ibrutinib Demonstrates Tolerability and Safety in Advanced B-Cell Malignancies: A Phase I Study
Open the PDF for Selinexor Combined with Ibrutinib Demonstrates Tolerability and Safety in Advanced B-Cell Malignancies: A Phase I Study in another window
Includes: Supplementary data
Journal Articles

Targeting DNA Damage Repair Functions of Two Histone Deacetylases, HDAC8 and SIRT6, Sensitizes Acute Myeloid Leukemia to NAMPT Inhibition

Pu Zhang, Lindsey T. Brinton, Katie Williams, Steven Sher, Shelley Orwick, Lai Tzung-Huei, Alice S. Mims, Christopher C. Coss, Samuel K. Kulp, Youssef Youssef, Wing Keung Chan, Shaneice Mitchell, Allison Mustonen, Matthew Cannon, Hannah Phillips, Amy M. Lehman, Tierney Kauffman, Larry Beaver, Daniel Canfield, Nicole R. Grieselhuber, Lapo Alinari, Deepa Sampath, Pearlly Yan, John C. Byrd, James S. Blachly, Rosa Lapalombella
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (8): 2352–2366.
https://doi.org/10.1158/1078-0432.CCR-20-3724
Published: 15 April 2021
View article titled, Targeting DNA Damage Repair Functions of Two Histone Deacetylases, HDAC8 and SIRT6, Sensitizes Acute Myeloid Leukemia to NAMPT Inhibition
Open the PDF for Targeting DNA Damage Repair Functions of Two Histone Deacetylases, HDAC8 and SIRT6, Sensitizes Acute Myeloid Leukemia to NAMPT Inhibition in another window
Includes: Supplementary data
Journal Articles

Early Intervention with Lenalidomide in Patients with High-risk Chronic Lymphocytic Leukemia

Shanmugapriya Thangavadivel, Qiuhong Zhao, Narendranath Epperla, Lindsey Rike, Xiaokui Mo, Mohamed Badawi, Darlene M. Bystry, Mitch A. Phelps, Leslie A. Andritsos, Kerry A. Rogers, Jeffrey Jones, Jennifer A. Woyach, John C. Byrd, Farrukh T. Awan
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (23): 6187–6195.
https://doi.org/10.1158/1078-0432.CCR-20-1280
Published: 01 December 2020
View article titled, Early Intervention with Lenalidomide in Patients with High-risk Chronic Lymphocytic Leukemia
Open the PDF for Early Intervention with Lenalidomide in Patients with High-risk Chronic Lymphocytic Leukemia in another window
Includes: Supplementary data
Journal Articles

Entospletinib in Combination with Induction Chemotherapy in Previously Untreated Acute Myeloid Leukemia: Response and Predictive Significance of HOXA9 and MEIS1 Expression

Alison R. Walker, John C. Byrd, James S. Blachly, Bhavana Bhatnagar, Alice S. Mims, Shelley Orwick, Tara L. Lin, Howland E. Crosswell, Danjie Zhang, Mark D. Minden, Veerendra Munugalavadla, Lauren Long, Jinfeng Liu, Yang Pan, Thomas Oellerich, Hubert Serve, Arati V. Rao, William G. Blum
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (22): 5852–5859.
https://doi.org/10.1158/1078-0432.CCR-20-1064
Published: 13 November 2020
View article titled, Entospletinib in Combination with Induction Chemotherapy in Previously Untreated Acute Myeloid Leukemia: Response and Predictive Significance of <em>HOXA9</em> and <em>MEIS1</em> Expression
Open the PDF for Entospletinib in Combination with Induction Chemotherapy in Previously Untreated Acute Myeloid Leukemia: Response and Predictive Significance of <em>HOXA9</em> and <em>MEIS1</em> Expression in another window
Includes: Supplementary data
Journal Articles

Ibrutinib Treatment for First-Line and Relapsed/Refractory Chronic Lymphocytic Leukemia: Final Analysis of the Pivotal Phase Ib/II PCYC-1102 Study

John C. Byrd, Richard R. Furman, Steven E. Coutre, Ian W. Flinn, Jan A. Burger, Kristie Blum, Jeff P. Sharman, William Wierda, Weiqiang Zhao, Nyla A. Heerema, Ying Luan, Emily A. Liu, James P. Dean, Susan O'Brien
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2020) 26 (15): 3918–3927.
https://doi.org/10.1158/1078-0432.CCR-19-2856
Published: 03 August 2020
View article titled, Ibrutinib Treatment for First-Line and Relapsed/Refractory Chronic Lymphocytic Leukemia: Final Analysis of the Pivotal Phase Ib/II PCYC-1102 Study
Open the PDF for Ibrutinib Treatment for First-Line and Relapsed/Refractory Chronic Lymphocytic Leukemia: Final Analysis of the Pivotal Phase Ib/II PCYC-1102 Study in another window
Includes: Supplementary data
Journal Articles

Genetic Characterization and Prognostic Relevance of Acquired Uniparental Disomies in Cytogenetically Normal Acute Myeloid Leukemia

Christopher J. Walker, Jessica Kohlschmidt, Ann-Kathrin Eisfeld, Krzysztof Mrózek, Sandya Liyanarachchi, Chi Song, Deedra Nicolet, James S. Blachly, Marius Bill, Dimitrios Papaioannou, Christopher C. Oakes, Brian Giacopelli, Luke K. Genutis, Sophia E. Maharry, Shelley Orwick, Kellie J. Archer, Bayard L. Powell, Jonathan E. Kolitz, Geoffrey L. Uy, Eunice S. Wang, Andrew J. Carroll, Richard M. Stone, John C. Byrd, Albert de la Chapelle, Clara D. Bloomfield
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (21): 6524–6531.
https://doi.org/10.1158/1078-0432.CCR-19-0725
Published: 01 November 2019
View article titled, Genetic Characterization and Prognostic Relevance of Acquired Uniparental Disomies in Cytogenetically Normal Acute Myeloid Leukemia
Open the PDF for Genetic Characterization and Prognostic Relevance of Acquired Uniparental Disomies in Cytogenetically Normal Acute Myeloid Leukemia in another window
Includes: Supplementary data
Journal Articles

Eμ-TCL1xMyc: A Novel Mouse Model for Concurrent CLL and B-Cell Lymphoma

Fabienne Lucas, Kerry A. Rogers, Bonnie K. Harrington, Alexander Pan, Lianbo Yu, Justin Breitbach, Ralf Bundschuh, Virginia M. Goettl, Zachary A. Hing, Parviz Kanga, Rose Mantel, Deepa Sampath, Lisa L. Smith, Ronni Wasmuth, Danielle K. White, Pearlly Yan, John C. Byrd, Rosa Lapalombella, Jennifer A. Woyach
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (20): 6260–6273.
https://doi.org/10.1158/1078-0432.CCR-19-0273
Published: 15 October 2019
View article titled, Eμ-TCL1xMyc: A Novel Mouse Model for Concurrent CLL and B-Cell Lymphoma
Open the PDF for Eμ-TCL1xMyc: A Novel Mouse Model for Concurrent CLL and B-Cell Lymphoma in another window
Includes: Supplementary data
Journal Articles

A Phase I/II Trial of Cetuximab in Combination with Interleukin-12 Administered to Patients with Unresectable Primary or Recurrent Head and Neck Squamous Cell Carcinoma

Elizabeth L. McMichael, Brooke Benner, Lakhvir S. Atwal, Nicholas B. Courtney, Xiaokui Mo, Melanie E. Davis, Amanda R. Campbell, Megan C. Duggan, Kallan Williams, Kyle Martin, Kala Levine, Gonzalo N. Olaverria Salavaggione, Tiffany Noel, Akaansha Ganju, Sarvani Uppati, Bonnie Paul, Thomas Olencki, Theodoros N. Teknos, Panos Savvides, Susheela Tridandapani, John C. Byrd, Michael A. Caligiuri, Stephen V. Liu, William E. Carson, III
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (16): 4955–4965.
https://doi.org/10.1158/1078-0432.CCR-18-2108
Published: 15 August 2019
View article titled, A Phase I/II Trial of Cetuximab in Combination with Interleukin-12 Administered to Patients with Unresectable Primary or Recurrent Head and Neck Squamous Cell Carcinoma
Open the PDF for A Phase I/II Trial of Cetuximab in Combination with Interleukin-12 Administered to Patients with Unresectable Primary or Recurrent Head and Neck Squamous Cell Carcinoma in another window
Includes: Supplementary data
Journal Articles

Nitric Oxide Production by Myeloid-Derived Suppressor Cells Plays a Role in Impairing Fc Receptor–Mediated Natural Killer Cell Function

Andrew Stiff, Prashant Trikha, Bethany Mundy-Bosse, Elizabeth McMichael, Thomas A. Mace, Brooke Benner, Kari Kendra, Amanda Campbell, Shalini Gautam, David Abood, Ian Landi, Vincent Hsu, Megan Duggan, Robert Wesolowski, Matthew Old, John Harrison Howard, Lianbo Yu, Nancy Stasik, Thomas Olencki, Natarajan Muthusamy, Susheela Tridandapani, John C. Byrd, Michael Caligiuri, William E. Carson
Journal: Clinical Cancer Research
Clin Cancer Res (2018) 24 (8): 1891–1904.
https://doi.org/10.1158/1078-0432.CCR-17-0691
Published: 12 April 2018
View article titled, Nitric Oxide Production by Myeloid-Derived Suppressor Cells Plays a Role in Impairing Fc Receptor–Mediated Natural Killer Cell Function
Open the PDF for Nitric Oxide Production by Myeloid-Derived Suppressor Cells Plays a Role in Impairing Fc Receptor–Mediated Natural Killer Cell Function in another window
Includes: Supplementary data
Journal Articles

The Bruton Tyrosine Kinase (BTK) Inhibitor Acalabrutinib Demonstrates Potent On-Target Effects and Efficacy in Two Mouse Models of Chronic Lymphocytic Leukemia

Sarah E.M. Herman, Arnau Montraveta, Carsten U. Niemann, Helena Mora-Jensen, Michael Gulrajani, Fanny Krantz, Rose Mantel, Lisa L. Smith, Fabienne McClanahan, Bonnie K. Harrington, Dolors Colomer, Todd Covey, John C. Byrd, Raquel Izumi, Allard Kaptein, Roger Ulrich, Amy J. Johnson, Brian J. Lannutti, Adrian Wiestner, Jennifer A. Woyach
Journal: Clinical Cancer Research
Clin Cancer Res (2017) 23 (11): 2831–2841.
https://doi.org/10.1158/1078-0432.CCR-16-0463
Published: 31 May 2017
View article titled, The Bruton Tyrosine Kinase (BTK) Inhibitor Acalabrutinib Demonstrates Potent On-Target Effects and Efficacy in Two Mouse Models of Chronic Lymphocytic Leukemia
Open the PDF for The Bruton Tyrosine Kinase (BTK) Inhibitor Acalabrutinib Demonstrates Potent On-Target Effects and Efficacy in Two Mouse Models of Chronic Lymphocytic Leukemia in another window
Includes: Supplementary data
Journal Articles

Extended Treatment with Single-Agent Ibrutinib at the 420 mg Dose Leads to Durable Responses in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Steven E. Coutré, Richard R. Furman, Ian W. Flinn, Jan A. Burger, Kristie Blum, Jeff Sharman, Jeffrey Jones, William Wierda, Weiqiang Zhao, Nyla A. Heerema, Amy J. Johnson, Anh Tran, Cathy Zhou, Elizabeth Bilotti, Danelle F. James, John C. Byrd, Susan O'Brien
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2017) 23 (5): 1149–1155.
https://doi.org/10.1158/1078-0432.CCR-16-1431
Published: 28 February 2017
View article titled, Extended Treatment with Single-Agent Ibrutinib at the 420 mg Dose Leads to Durable Responses in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Open the PDF for Extended Treatment with Single-Agent Ibrutinib at the 420 mg Dose Leads to Durable Responses in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma in another window
Includes: Supplementary data
Journal Articles

Abstract B19: Population pharmacokinetic-pharmacodynamic (PKPD) modeling of ibrutinib in patients with B-cell malignancies.

Italo Poggesi, Maria Luisa Sardu, Eleonora Marostica, Juthamas Sukbuntherng, Betty Y. Chang, Jan de Jong, Xavier Woot de Trixhe, An Vermeulen, Giuseppe De Nicolao, Susan Mary O'Brien, John C Byrd, Ranjana H Advani, Danelle Frances James, William Deraedt, Darrin Beaupre, Michael Wang
Journal: Clinical Cancer Research
Clin Cancer Res (2015) 21 (17_Supplement): B19.
https://doi.org/10.1158/1557-3265.HEMMAL14-B19
Published: 19 August 2015
View article titled, Abstract B19: Population pharmacokinetic-pharmacodynamic (PKPD) modeling of ibrutinib in patients with B-cell malignancies.
Journal Articles

New Strategies in Chronic Lymphocytic Leukemia: Shifting Treatment Paradigms

Farrukh T. Awan, John C. Byrd
Journal: Clinical Cancer Research
Clin Cancer Res (2014) 20 (23): 5869–5874.
https://doi.org/10.1158/1078-0432.CCR-14-1889
Published: 30 November 2014
View article titled, New Strategies in Chronic Lymphocytic Leukemia: Shifting Treatment Paradigms
Open the PDF for New Strategies in Chronic Lymphocytic Leukemia: Shifting Treatment Paradigms in another window
Journal Articles

Targeted Delivery of microRNA-29b by Transferrin-Conjugated Anionic Lipopolyplex Nanoparticles: A Novel Therapeutic Strategy in Acute Myeloid Leukemia

Xiaomeng Huang, Sebastian Schwind, Bo Yu, Ramasamy Santhanam, Hongyan Wang, Pia Hoellerbauer, Alice Mims, Rebecca Klisovic, Alison R. Walker, Kenneth K. Chan, William Blum, Danilo Perrotti, John C. Byrd, Clara D. Bloomfield, Michael A. Caligiuri, Robert J. Lee, Ramiro Garzon, Natarajan Muthusamy, Ly James Lee, Guido Marcucci
Journal: Clinical Cancer Research
Clin Cancer Res (2013) 19 (9): 2355–2367.
https://doi.org/10.1158/1078-0432.CCR-12-3191
Published: 30 April 2013
View article titled, Targeted Delivery of <em>microRNA-29b</em> by Transferrin-Conjugated Anionic Lipopolyplex Nanoparticles: A Novel Therapeutic Strategy in Acute Myeloid Leukemia
Open the PDF for Targeted Delivery of <em>microRNA-29b</em> by Transferrin-Conjugated Anionic Lipopolyplex Nanoparticles: A Novel Therapeutic Strategy in Acute Myeloid Leukemia in another window
Includes: Supplementary data
Journal Articles

The Proteasome Inhibitor Carfilzomib Functions Independently of p53 to Induce Cytotoxicity and an Atypical NF-κB Response in Chronic Lymphocytic Leukemia Cells

Sneha V. Gupta, Erin Hertlein, Yanhui Lu, Ellen J. Sass, Rosa Lapalombella, Timothy L. Chen, Melanie E. Davis, Jennifer A. Woyach, Amy Lehman, David Jarjoura, John C. Byrd, David M. Lucas
Journal: Clinical Cancer Research
Clin Cancer Res (2013) 19 (9): 2406–2419.
https://doi.org/10.1158/1078-0432.CCR-12-2754
Published: 30 April 2013
View article titled, The Proteasome Inhibitor Carfilzomib Functions Independently of p53 to Induce Cytotoxicity and an Atypical NF-κB Response in Chronic Lymphocytic Leukemia Cells
Open the PDF for The Proteasome Inhibitor Carfilzomib Functions Independently of p53 to Induce Cytotoxicity and an Atypical NF-κB Response in Chronic Lymphocytic Leukemia Cells in another window
Includes: Supplementary data
Journal Articles

A Pharmacokinetic/Pharmacodynamic Model of Tumor Lysis Syndrome in Chronic Lymphocytic Leukemia Patients Treated with Flavopiridol

Jia Ji, Diane R. Mould, Kristie A. Blum, Amy S. Ruppert, Ming Poi, Yuan Zhao, Amy J. Johnson, John C. Byrd, Michael R. Grever, Mitch A. Phelps
Journal: Clinical Cancer Research
Clin Cancer Res (2013) 19 (5): 1269–1280.
https://doi.org/10.1158/1078-0432.CCR-12-1092
Published: 03 March 2013
View article titled, A Pharmacokinetic/Pharmacodynamic Model of Tumor Lysis Syndrome in Chronic Lymphocytic Leukemia Patients Treated with Flavopiridol
Open the PDF for A Pharmacokinetic/Pharmacodynamic Model of Tumor Lysis Syndrome in Chronic Lymphocytic Leukemia Patients Treated with Flavopiridol in another window
Includes: Supplementary data
Journal Articles

Milatuzumab-Conjugated Liposomes as Targeted Dexamethasone Carriers for Therapeutic Delivery in CD74+ B-cell Malignancies

Yicheng Mao, Georgia Triantafillou, Erin Hertlein, William Towns, Matthew Stefanovski, Xiaokui Mo, David Jarjoura, Mitch Phelps, Guido Marcucci, Ly James Lee, David M. Goldenberg, Robert J. Lee, John C. Byrd, Natarajan Muthusamy
Journal: Clinical Cancer Research
Clin Cancer Res (2013) 19 (2): 347–356.
https://doi.org/10.1158/1078-0432.CCR-12-2046
Published: 16 January 2013
View article titled, Milatuzumab-Conjugated Liposomes as Targeted Dexamethasone Carriers for Therapeutic Delivery in CD74<sup>+</sup> B-cell Malignancies
Open the PDF for Milatuzumab-Conjugated Liposomes as Targeted Dexamethasone Carriers for Therapeutic Delivery in CD74<sup>+</sup> B-cell Malignancies in another window
Includes: Supplementary data
Journal Articles

A Phase I Dose-Finding Trial of Recombinant Interleukin-21 and Rituximab in Relapsed and Refractory Low Grade B-cell Lymphoproliferative Disorders

John M. Timmerman, John C. Byrd, David J. Andorsky, Reiko E. Yamada, Janet Kramer, Natarajan Muthusamy, Naomi Hunder, John M. Pagel
Journal: Clinical Cancer Research
Clin Cancer Res (2012) 18 (20): 5752–5760.
https://doi.org/10.1158/1078-0432.CCR-12-0456
Published: 14 October 2012
View article titled, A Phase I Dose-Finding Trial of Recombinant Interleukin-21 and Rituximab in Relapsed and Refractory Low Grade B-cell Lymphoproliferative Disorders
Open the PDF for A Phase I Dose-Finding Trial of Recombinant Interleukin-21 and Rituximab in Relapsed and Refractory Low Grade B-cell Lymphoproliferative Disorders in another window
Includes: Supplementary data
Journal Articles

FTY720 Shows Promising In vitro and In vivo Preclinical Activity by Downmodulating Cyclin D1 and Phospho-Akt in Mantle Cell Lymphoma

Qing Liu, Lapo Alinari, Ching-Shih Chen, Fengting Yan, James T. Dalton, Rosa Lapalombella, Xiaoli Zhang, Rajeswaran Mani, Teresa Lin, John C. Byrd, Robert A. Baiocchi, Natarajan Muthusamy
Journal: Clinical Cancer Research
Clin Cancer Res (2010) 16 (12): 3182–3192.
https://doi.org/10.1158/1078-0432.CCR-09-2484
Published: 14 June 2010
View article titled, FTY720 Shows Promising <em>In vitro</em> and <em>In vivo</em> Preclinical Activity by Downmodulating Cyclin D1 and Phospho-Akt in Mantle Cell Lymphoma
Open the PDF for FTY720 Shows Promising <em>In vitro</em> and <em>In vivo</em> Preclinical Activity by Downmodulating Cyclin D1 and Phospho-Akt in Mantle Cell Lymphoma in another window